QuPath is new bioimage analysis software designed to meet the growing need for a user-friendly, extensible, open-source solution for digital pathology and whole slide image analysis. In addition to offering a comprehensive panel of tumor identification and high-throughput biomarker evaluation tools, QuPath provides researchers with powerful batch-processing and scripting functionality, and an extensible platform with which to develop and share new algorithms to analyze complex tissue images. Furthermore, QuPath's flexible design makes it suitable for a wide range of additional image analysis applications across biomedical research.
Introduction
The ability to acquire high resolution digital scans of entire microscopic slides with high-resolution whole slide scanners is transforming tissue biomarker and companion diagnostic discovery through digital image analytics, automation, quantitation and objective screening of tissue samples. This area has become widely known as digital pathology 1, 2 provided opportunities for the field of image analysis to add considerably to 4 translational research by enabling the development of the bespoke analytical methods that are essential to address specific issues. There has, however, been an absence of tools to tackle the specific visualization and computational challenges posed by whole slide images (WSI) and very large 2D data, and this has created a major bottleneck in the pathological tissue assessment pipeline 7 . Consequently, the field of digital pathology continues to lack a commonly-accepted, open and accessible software framework for distributing novel algorithms, and has been slow to embrace the 'call for bioimaging software usability' 8 . In practice, this has meant that users without access to expensive commercial solutions have had to either resort to inefficient workarounds (such as image downsampling and cropping) to be able to apply general open source analysis tools to a subset of their data 9,10 , or to rely primarily on laborious manual evaluation of slides, which is known to have high variability and limited reproducibility 11,12 .
QuPath (https://qupath.github.io) has been developed to address these needs by offering the first comprehensive, open source platform specifically designed for whole slide applications. At its core is a cross-platform, multithreaded, tile-based whole slide image viewer, which incorporates extensive annotation and visualization tools. On top of this, QuPath offers an array of novel algorithms to provide not only ready-made, user-friendly solutions to common, challenging analysis problems in pathology, but also the building blocks to create custom workflows -and link these together for batch processing with powerful scripting functionality ( Fig. 1) . Finally, QuPath enables developers to add their own extensions to solve new challenges and applications, and to exchange data in a streamlined manner with existing tools that otherwise lack whole slide support, such as ImageJ and MATLAB.
A key feature underpinning QuPath's functionality, and a major technical distinguishing factor between QuPath and other bioimaging analysis software, is its hierarchical, 'object-based' data model. Here, an 'object' refers to a structure or region within the image, which may be created and manipulated by either interactive drawing tools (e.g. to annotate a particular region of interest) or automated segmentation commands (e.g. to detect individual nuclei or cells). This generic model allows QuPath to represent and display relationships between very large numbers of image objects in an efficient and intuitive manner across gigapixel images, and support the fast and interactive training of object classifiers using machine learning techniques. 
Results and Discussion
To demonstrate some of these capabilities, including its biological and clinical validity, we used QuPath to analyze several image sets derived from surgical resection specimens from a population-based cohort of 660 patients with stage II and stage III colon cancer, diagnosed between 2004-2008 (392 stage II, 268 stage III) and with high-quality curation of clinicopathological information. From representative paraffin-embedded tumor blocks, provided via the Northern Ireland Biobank, whole sections were haematoxylin and eosin-stained in the Northern Ireland Molecular Pathology Laboratory. Tissue microarrays (TMAs) were generated from representative 1mm diameter tumor cores from each case, sampled in triplicate from the tumor center after annotation.
The aim was to test the performance of QuPath in the context of known and novel biological and clinical data, using cancer immunology and tumor suppressor genes as paradigms.
Firstly, we applied QuPath to analyze TMAs immunohistochemically-stained (IHC) for the T cell markers CD3 and CD8.
Following digital scanning of the WSI, the initial QuPath setup required importing the images, applying automated 'dearraying' to identify tissue cores, manually refining the resulting dearrayed grid, and removing cores unsuitable for analysis.
After this step, batch analysis was applied across all TMA slides to identify the tissue within each core and automatically count the number of positive cells per mm 2 tissue based upon a fast peak-finding algorithm after stain separation by color deconvolution 13 (Supplementary Fig. 1, Supplementary Video 1) . Next, we used QuPath to evaluate immunohistochemistry for p53 in a second set of TMAs from the same cohort. This required a more sophisticated analysis to encompass the biological understanding and staining pattern of the marker. After applying QuPath's cell detection algorithm to segment and measure cells within each core, a random trees classifier 15 was interactively trained to enable p53 expression to be scored selectively within the epithelial cell population according to nuclear staining intensity and proportion ( Supplementary Fig. 2 We then applied QuPath to the analysis of programmed cell death ligand 1 (PD-L1) immunoexpression in the same TMA cohort. PD-L1 immunoexpression is a prognostic marker in a range of cancer types and also a predictor of response to immune checkpoint therapy in some cancers 19, 20 . However, there is a lack of consensus on the epitopes of clinical relevance and, more importantly, the optimal scoring systems for evaluation. The approach to analysis was similar in principle to that adopted for p53, however further attention was required because of additional challenges posed by PD-L1 immunostaining. Firstly, staining is cytoplasmic and/or membranous rather than nuclear. Secondly, PD-L1 can be expressed in tumor epithelium, but is more commonly expressed in other tissue compartments, notably within peritumoral stromal inflammatory cells. Although this level of heterogeneity in staining pattern is increasingly being recognised, the clinical importance of distinguishing tumor epithelial from inflammatory cell
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staining is yet to be fully understood. Sufficient cell classification is therefore required to identify both positively and negatively staining tumor (epithelial) and non-tumor cell populations, in addition to distinguishing true protein expression levels from the various staining artefacts that are inherent with IHC-based tissue analysis. Here, applying QuPath, a cell was classified as positive or negative based on maximal DAB staining intensity, as a surrogate marker of protein expression, within a full cell region approximated by expanding detected nuclei ( Supplementary Fig. 3) . Across the cohort, a median cutoff of 1.46% of all cells exhibiting PD-L1 positivity according to this definition was applied to stratify patients, showing high PD-L1 expression to be significantly associated with improved disease-specific survival in unadjusted analysis (p=0.004, Fig. 2d ).
Additionally, an analysis based on tertiles exhibited a dose-response effect, and separation of the tumor (epithelial) and non-epithelial components suggested that PD-L1 expression in colon cancer tissue is primarily found in the non-epithelial compartment (Supplementary Fig. 4) . These results support the incipient evidence of PD-L1 prognostic value in colorectal cancer reported by ourselves and others in independent cohorts [20] [21] [22] , and may be of help when used together with tumor microsatellite instability status for patient stratification in consideration of anti-PD-L1 therapy.
Finally, to demonstrate QuPath's flexibility beyond IHC scoring in TMAs, we applied texture-based analysis to calculate the tumor stromal percentage in whole face representative tumor sections stained with hematoxylin and eosin (H&E) from 312 patients with stage II colon cancer from the same cohort. Several studies have reported that a higher intratumoral stromal percentage correlates with a worse prognosis in patients with stage II and stage III colorectal cancer 23, 24 . Given highly variable clinical outcomes within stage II disease, there is a particular need for additional prognostic features in this group, to identify those patients most likely to benefit from adjuvant chemotherapy. These studies employed a crude visual estimate of tumor stromal percentage. Applying QuPath's more finegrained and reproducible assessment, and a median cutoff for analysis, we found lower disease-specific survival among patients with a high tumor stromal percentage in unadjusted analysis (p=0.013; Fig. 2e ), consistent with previous findings 23, 24 .
In 
Materials and Methods

Cohort
Image data acquisition
All TMA slides were scanned using an Aperio ScanScope CS whole slide scanner at 40X magnification, with a resolution of 0.25 μm/pixel. H&E slide scanning was heterogenous: 231 were scanned on the Aperio ScanScope scanner, while 81
were scanned on a Hamamatsu Nanozoomer. The resolution of all images was within the range 0.231 -0.253 μm/pixel.
Software
QuPath was written as a novel, cross-platform Java application. The core software was developed using Java 8, with a user interface written using JavaFX.
Whole slide image reading was achieved using QuPath's interfaces to the OpenSlide library 25 
Code availability
Source code and documentation for QuPath are available at https://qupath.github.io
Statistical analysis
Survival curves using the Kaplan Meier method were generated and log-rank tests applied using the TMA data viewer within QuPath, and independently Stratification based on tertiles is also provided in the Supplementary Materials for PD-L1.
For TMA analysis, up to three tissue cores were available from each tumor, all selected from the same paraffin block representing the central tumor region. A single patient biomarker score was defined as the median of all available scores for the corresponding patient and biomarker. The median was chosen to aid the 16 robustness of the measurement in a high-throughput setting, and reduce the likelihood of basing the score for any individual patient on an outlier that may have been caused by a tissue or staining artefact.
Tissue microarray preprocessing
Separate projects were created within QuPath for each biomarker, and the slide images imported to the corresponding projects. QuPath's automated TMA dearrayer was applied in batch over all slides within each project to identify tissue cores. The resulting TMA grid was manually verified and amended where necessary, e.g. to adjust the locations of cores that were outside their expected position, or to remove cores where prominent artefacts were visible. Patient identifiers were then imported into QuPath for each core to assist alignment with survival data later. Additionally, stain vector (i.e. color) and background estimates were applied for each IHC analysis project to improve stain separation within QuPath using color deconvolution 13 . This was achieved by selecting a representative area containing an area of background along with examples of strong hematoxylin and DAB staining, and applying QuPath's Estimate stain vectors command to identify stain vectors within this region. The resulting vectors were then used for all images in the project.
Analysis of CD3 and CD8 IHC
After the initial TMA preprocessing steps described above, analysis of CD3 and 2). Intensity thresholds were set to further subclassify tumor cells as being negative, weak, moderate or strongly positive for p53 staining based upon mean nuclear DAB optical densities. An H-score was calculated for each tissue core by adding 3×% strongly stained tumor nuclei, 2×% moderately stained tumor nuclei, and 1×% weakly stained tumor nuclei 28 , giving results in the range 0 (all tumor nuclei negative) to 300 (all tumor nuclei strongly positive).
Analysis of PD-L1 IHC
The approach to scoring PD-L1 was similar to p53, apart from the following: 1) a three-way random trees classifier was trained to distinguish between epithelial, non-epithelial and 'other' detections (including artefacts and necrosis); 2) cells were classified as positive or negative based upon a single intensity threshold applied to the maximum DAB optical density within the full cell area, and 3) summary scores were generated as the percentage of cells classified as positive, with 'other' detections removed. 
Analysis of tumor stromal percentage in H&E whole face sections
